Objectives:

This study assesses whether the relationship of lipoprotein(a) [Lp(a)] with cardiovascular risk may be modified by concurrent hormone replacement therapy (HT).

Background:

Prior studies indicate that HT decreases plasma levels of Lp(a), but few have been powered to assess whether it modifies the relationship of Lp(a) with cardiovascular disease (CVD).

Methods:

Lipoprotein(a) at baseline was measured among 27,736 initially healthy women, of whom 12,075 indicated ...

Esta siendo redirigido al contenido completo...